SITUS JUDI MBL77 - AN OVERVIEW

mutations provided The reality that, as spelled out below, CLL therapy is based about the presence or absence of such mutations. The present consensus is that, besides clonal mutations, subclonal mutations using a variant allelic frequency ranging from 5 to ten% (and so underneath the edge of detection by regular molecular tactics) may be reported,